Safety and PK of Aderamastat in Healthy Subjects

Phase 1, randomised, double-blind trial of aderamastat in asthma, chronic obstructive pulmonary disease (COPD) and pulmonary fibrosis (PF) (5 arms), sponsored by Foresee Pharmaceuticals. Primary endpoints: Treatment-emergent Adverse Events, Serious Adverse Events, and ECG abnormalities at 17 days and Change from baseline for vital sign, ECG parameters, and clinical laboratory test at 17 days. Started Jul 2017; status: completed.